EMA: Should The Comparative Efficacy Requirement Be Waived For Biosimilars?

 
• By Ian Schofield
  
Clinical Trial New Vaccine Testing Medicine Drug 3d Illustration
Regulators are considering dropping comparative efficacy trial requirements for biosimilars • Source: Shutterstock

More from Europe

More from Geography